Alyeska Investment Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Alyeska Investment Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$5.42M	–	608
2024 Q4	$5.42M	Hold	100,000	–	–	0.02%	394
2024 Q3	$5.04M	Sell	100,000 -25,000	-20%	-$1.17M	0.03%	355
2024 Q2	$5.5M	Buy	+125,000	New	+$5.29M	0.03%	326
2024 Q1	–	Sell	-50,000	Closed	-$3.02M	–	556
2023 Q4	$3.02M	Buy	+50,000	New	+$2.58M	0.02%	339
2023 Q3	–	Sell	-57,347	Closed	-$2.92M	–	576
2023 Q2	$2.92M	Buy	+57,347	New	+$1.54M	0.02%	381
2022 Q1	–	Sell	-320,000	Closed	-$3.17M	–	637
2021 Q4	$3.17M	Hold	320,000	–	–	0.04%	364
2021 Q3	$3.18M	Hold	320,000	–	–	0.04%	414
2021 Q2	$3.31M	Hold	320,000	–	–	0.04%	426
2021 Q1	$3.26M	Hold	320,000	–	–	0.04%	392
2020 Q4	$3.64M	Buy	+320,000	New	+$3.4M	0.05%	318

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Alyeska Investment Group's MLTX Position: Q1 2025 in Review

Alyeska Investment Group sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 100,000 shares — an estimated $5.42M sold.

Alyeska Investment Group first reported a position in MLTX in Q4 2020 and held it in 10 quarters. The position peaked at $5.5M in Q2 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

Alyeska Investment Group reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
Alyeska Investment Group sold 100,000 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $5.42M.
Alyeska Investment Group first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 10 quarters.
Alyeska Investment Group's MoonLake Immunotherapeutics position peaked at $5.5M in Q2 2024.
136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on Alyeska Investment Group's 13F filing for Q1 2025, filed 15 May 2025.